Antonio Sabljić

Dr. Antonio Sabljić

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2026 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
ASAntonio Sabljić
Antonio Sabljić
DČDoris Čarija
Doris Čarija
KBKarolina Begić
Karolina Begić
RORenata Odžak
Renata Odžak
RČRozelindra Čož-Rakovac
Rozelindra Čož-Rakovac
MŠMatilda Šprung
Matilda Šprung
Bacterial resistance and the cytotoxicity of conventional quaternary ammonium compounds (QACs) highlight the necessity for safer and more effective membrane-active antibacterials. This study aimed to synthesize a homologous series of quinuclidin-3-one-based QACs (QO-C12, QO-C14, and QO-C16) and to elucidate their structure–activity relationships through comprehensive antibacterial, antibiofilm, cytotoxicity, embryotoxicity, mechanistic, and physicochemical analyses. The compounds were evaluated against clinically relevant pathogens using broth microdilution, growth and time-kill assays, biofilm inhibition testing, membrane permeabilization analysis, cytotoxicity testing in human retinal pigment epithelial (RPE1) and human embryonic kidney (HEK293) cells, zebrafish embryotoxicity assessments, and critical micelle concentration (CMC) measurements. Antibacterial potency was found to increase with alkyl chain length, with QO-C16 exhibiting the highest activity, including minimum inhibitory concentrations (MICs) of 8 µM against Staphylococcus aureus (including methicillin-resistant strains) and 4 µM against Listeria monocytogenes. In Dulbecco's modified Eagle medium (DMEM), MIC values were up to 32-fold lower than those observed in broth media, indicating a significant medium-dependent effect. QO-C14 and QO-C16 demonstrated robust antibiofilm activity, while QO-C16 produced the fastest bactericidal and membrane-disruptive effects. The critical micelle concentration decreased with increasing chain length, aligning with enhanced hydrophobicity and membrane affinity. Compared to commercial QACs, the novel compounds exhibited lower cytotoxicity in human cell lines; however, zebrafish embryotoxicity did increase with chain length. Overall, quinuclidin-3-one represents a promising scaffold for the development of QACs, with QO-C16 identified as the lead compound for further optimization toward selective antibacterial agents.

28 August 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ASAntonio Sabljić
Antonio Sabljić
DČDoris Čarija
Doris Čarija
ARAlma Ramic
Alma Ramic
MŠMatilda Šprung
Matilda Šprung
Renata OdžakRenata Odžak
Renata Odžak
Background: The increasing prevalence of antibiotic-resistant bacterial strains highlights the urgent need for new membrane-targeting antimicrobial agents. Bisquaternary ammonium compounds (bisQACs) have attracted attention for their ability to disrupt bacterial membranes more effectively than monoquaternary analogs. Quinuclidine, known for its health-beneficial properties, has previously been explored for monoQAC derivatization, but studies using natural scaffolds to generate bisQACs remain limited. Methods: Here, we synthesized twelve novel quinuclidine-based bisQACs, systematically varying alkyl chain and linker lengths to investigate structure–activity relationships. Results: Several compounds, including 2(QC16)3, 2(QC16)4, 2(QC14)6, and 2(QC16)6, exhibited strong activity against Staphylococcus aureus (including MRSA), Listeria monocytogenes, and Escherichia coli, with 2(QC16)6 being the most potent (MICs 5–38 µM). While cytotoxicity was observed on human RPE1 and HEK293 cells, selectivity indices indicated a favorable therapeutic window relative to reference QACs. Conclusions: These compounds also inhibited biofilm formation and induced rapid bacterial killing through a membrane-disruptive mode of action. Molecular docking showed that alkyl chain and linker variations modulate binding to the QacR efflux regulator, revealing a lower potential for efflux-mediated resistance. Overall, quinuclidine-based bisQACs represent promising leads for potent, selectively active next-generation antimicrobials with a reduced likelihood of resistance development.